XPO1 and Miyoshi myopathy: Our findings show that XPO1 inhibitors, when used in combination with PIs, are highly effective against acquired PI-resistant human MM in in vitro assays with PI-resistant cell lines, in vivo in mice challenged with PI-resistant MM tumors, and ex vivo in patient MM cells that are refractory to PIs.